Reviewer’s report

**Title:** Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection

**Version:** 4 **Date:** 23 December 2008

**Reviewer:** Thomas R Kreil

**Reviewer’s report:**

The authors have mostly responded to the comments provided, in an adequate fashion.

The one issue that still needs correction, in our mind, is the emphasis put onto the "... good correlation between ELISA results and the in vivo model ...", which in the view of the authors "... fully justifies the use of ELISA for screening of plasma ...": the data provided to support this authoritative claim is, however, insufficient, particularly in view of the potential medical application (!).

It is thus suggested to either generate a full validation of the suggested correlation according to ICH principles, or to delete the sentence on page 13 / line 15-17 before publication, so that misperceptions may not arise which are ill-founded in data.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

Dr. Thomas R. Kreil is employed by Baxter BioScience, a company that has conducted research into the use of IVIG for the potential prevention and treatment of virus infections, including West Nile Virus.